secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2025-09-16T23:59:59+00:00
Accession:  0001193125-25-204991
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics provides FDA/EMA update on aficamten; plans to draw $100M Royalty Pharma loan
--------------------------------------------------------------------------------

- FDA Late Cycle Meeting held; discussed REMS and label for aficamten in oHCM; PDUFA date remains Dec 26, 2025.
- GCP inspections completed with no observations; no GMP inspections scheduled for aficamten.
- Submitted responses to CHMP Day 120 questions from EMA for aficamten potential EU approval.
- Intends to draw full $100M Tranche 5 term loans from Royalty Pharma on or about October 1, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000119312525204991/0001193125-25-204991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000119312525204991/d66361d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-204991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer